Total | FSS (N%) | Radical surgery (N%) | |
---|---|---|---|
Total | 92 | 54 (58.7) | 38 (41.3) |
FIGO stage | |||
IA | 35 (38) | 31 (57.4) | 4 (10.5) |
IB | 9 (9.8) | 3 (5.6) | 6 (15.8) |
IC | 18 (19.6) | 8 (14.8) | 10 (26.3) |
II | 8 (8.7) | 1 (1.9) | 7 (18.4)) |
III | 22 (23.9) | 11 (20.4) | 11 (28.9) |
Diameter | |||
< 10 cm | 50 (54.3) | 27 (50.0) | 23 (60.5) |
≥ 10 cm | 42 (45.7) | 27 (50.0) | 15 (39.5) |
Histology | |||
Serous | 46 (50) | 26 (48.1) | 20 (52.6) |
Mucinous | 38 (41.3) | 25 (46.3) | 13 (34.2) |
Endometrioid | 7 (7.6) | 2 (3.7) | 5 (13.2) |
Serous and mucinous | 1 (1.1) | 1 (1.9) | 0 (0) |
Lesion lateral | |||
Left | 44 (47.8) | 26 (48.1) | 18 (47.4) |
Right | 29 (31.5) | 17 (31.5) | 12 (31.6) |
Bilateral | 19 (20.7) | 11 (20.4) | 8 (21.1) |
Rupture | |||
Yes | 17 (18.5) | 10 (18.5) | 7 (18.4) |
No | 75 (81.5) | 44 (81.5) | 31 (81.6) |
Micropapillary | |||
Yes | 16 (17.4) | 11 (20.4) | 5 (13.2) |
No | 76 (82.6) | 43 (79.6) | 33 (86.8) |
Microinvasion | |||
Yes | 7 (7.6) | 5 (9.3) | 2 (5.3) |
No | 85 (92.4) | 49 (90.7) | 36 (94.7) |
Invasive implants | |||
Yes | 4 (4.3) | 2 (3.7) | 2 (5.3) |
No | 88 (95.7) | 52 (96.3) | 36 (94.7) |
Pelvic lymph node | |||
Positive | 10 (10.9) | 6 (11.1) | 4 (10.5) |
Negative | 82 (89.1) | 48 (88.9) | 34 (89.5) |
Para-aortic lymph node | |||
Positive | 3 (3.3) | 2 (3.7) | 1 (2.6) |
Negative | 89 (96.7) | 52 (96.3) | 37 (97.4) |
Lymphadenectomy | |||
Yes | 55 (59.8) | 26 (48.1) | 29 (76.3) |
No | 37 (40.2) | 28 (51.9) | 9 (23.7) |
Surgery approach | |||
Laparoscopy | 7 (7.6) | 5 (9.3) | 2 (5.3) |
Laparotomy | 85 (92.4) | 49 (90.7) | 36 (94.7) |
Adjuvant chemotherapy | |||
Yes | 10 (10.9) | 4 (7.4) | 6 (15.8) |
No | 82 (89.1) | 50 (92.6) | 32 (84.2) |
Staging surgery | |||
Yes | 87 (94.6) | 51 (94.4) | 36 (94.7) |
No | 5 (5.4) | 3 (5.6) | 2 (5.3) |
Appendectomy | |||
Yes | 8 (8.7) | 5 (9.3) | 3 (7.9) |
No | 84 (91.3) | 49 (90.7) | 35 (92.1) |
Recurrence | |||
Yes | 22 (23.9) | 19 (35.2) | 3 (7.9) |
No | 70 (76.1) | 35 (64.8) | 35 (92.1) |
Death | 0 | 0 | 0 |